Logo image of ALEC

ALECTOR INC (ALEC) Stock Price, Quote, News and Overview

NASDAQ:ALEC - Nasdaq - US0144421072 - Common Stock - Currency: USD

1.87  +0.01 (+0.54%)

After market: 1.87 0 (0%)

ALEC Quote, Performance and Key Statistics

ALECTOR INC

NASDAQ:ALEC (2/21/2025, 8:00:49 PM)

After market: 1.87 0 (0%)

1.87

+0.01 (+0.54%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High7.58
52 Week Low1.55
Market Cap183.13M
Shares97.93M
Float88.14M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)02-26 2025-02-26/amc
IPO02-07 2019-02-07


ALEC short term performance overview.The bars show the price performance of ALEC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

ALEC long term performance overview.The bars show the price performance of ALEC in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of ALEC is 1.87 USD. In the past month the price increased by 3.31%. In the past year, price decreased by -70.83%.

ALECTOR INC / ALEC Daily stock chart

ALEC Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About ALEC

Company Profile

ALEC logo image Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 241 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration diseases. The firm is engaged in developing therapies designed to counteract these pathologies simultaneously by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its product candidates: latozinemab (AL001), AL002, and AL101, are in clinical development. Its immune-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients.

Company Info

ALECTOR INC

131 Oyster Point Blvd., Suite 600

South San Francisco CALIFORNIA 94080 US

CEO: Arnon Rosenthal

Employees: 245

Company Website: https://alector.com

Investor Relations: https://investors.alector.com/

Phone: 14152315660

ALECTOR INC / ALEC FAQ

What is the stock price of ALECTOR INC today?

The current stock price of ALEC is 1.87 USD. The price increased by 0.54% in the last trading session.


What is the ticker symbol for ALECTOR INC stock?

The exchange symbol of ALECTOR INC is ALEC and it is listed on the Nasdaq exchange.


On which exchange is ALEC stock listed?

ALEC stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALECTOR INC stock?

15 analysts have analysed ALEC and the average price target is 4.93 USD. This implies a price increase of 163.63% is expected in the next year compared to the current price of 1.87. Check the ALECTOR INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALECTOR INC worth?

ALECTOR INC (ALEC) has a market capitalization of 183.13M USD. This makes ALEC a Micro Cap stock.


How many employees does ALECTOR INC have?

ALECTOR INC (ALEC) currently has 245 employees.


What are the support and resistance levels for ALECTOR INC (ALEC) stock?

ALECTOR INC (ALEC) has a support level at 1.65 and a resistance level at 1.88. Check the full technical report for a detailed analysis of ALEC support and resistance levels.


Is ALECTOR INC (ALEC) expected to grow?

The Revenue of ALECTOR INC (ALEC) is expected to decline by -31.32% in the next year. Check the estimates tab for more information on the ALEC EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ALECTOR INC (ALEC) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALECTOR INC (ALEC) stock pay dividends?

ALEC does not pay a dividend.


When does ALECTOR INC (ALEC) report earnings?

ALECTOR INC (ALEC) will report earnings on 2025-02-26, after the market close.


What is the Price/Earnings (PE) ratio of ALECTOR INC (ALEC)?

ALECTOR INC (ALEC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.7).


What is the Short Interest ratio of ALECTOR INC (ALEC) stock?

The outstanding short interest for ALECTOR INC (ALEC) is 6.43% of its float. Check the ownership tab for more information on the ALEC short interest.


ALEC Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to ALEC. When comparing the yearly performance of all stocks, ALEC is a bad performer in the overall market: 97.81% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALEC Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ALEC. ALEC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALEC Financial Highlights

Over the last trailing twelve months ALEC reported a non-GAAP Earnings per Share(EPS) of -1.7. The EPS decreased by -0.59% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -30.7%
ROE -133.19%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%18.87%
Sales Q2Q%68.43%
EPS 1Y (TTM)-0.59%
Revenue 1Y (TTM)-36.06%

ALEC Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 77% to ALEC. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of -22.77% and a revenue growth -31.32% for ALEC


Ownership
Inst Owners87.59%
Ins Owners7.25%
Short Float %6.43%
Short Ratio5.2
Analysts
Analysts77.33
Price Target4.93 (163.64%)
EPS Next Y-22.77%
Revenue Next Year-31.32%